ADI-PEG 20 + TMZ + RT for Brain Cancer

This trial explores a new combination of treatments for young patients with newly diagnosed high-grade glioma, a type of brain cancer. It combines the experimental drug ADI-PEG 20 with Temozolomide, a chemotherapy drug, and radiation therapy to assess potential improvements in treatment outcomes. The trial includes different groups to evaluate the treatment's effects on specific glioma types, such as histone wild-type and H3K27 altered diffuse midline gliomas. Patients who have undergone surgery for a high-grade glioma but have not yet received other treatments may be suitable candidates for this study. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this new combination therapy.

The trial does not specify if you need to stop taking your current medications, but it does mention that participants must not have received any prior therapy except surgery before enrolling. If you are on medications, especially for seizures, you may need to discuss potential interactions with the study drug with the trial team.

In earlier studies, ADI-PEG 20 showed promise for treating brain tumors. Research suggests it increases tumor sensitivity to radiation therapy, aiding in shrinkage. The combination of ADI-PEG 20 with radiation and temozolomide (TMZ) proved safe. Some participants developed antibodies against ADI-PEG 20, but this did not cause major issues.

Temozolomide is a standard treatment for aggressive brain tumors and is generally safe. Some studies report blood-related side effects in 5 to 10% of patients, but it is mostly well-tolerated over long periods.

Researchers are excited about ADI-PEG 20 for brain cancer because it offers a unique approach by depleting arginine, an amino acid that some tumors rely on to grow. Most existing treatments, like surgery, radiation, and chemotherapies such as temozolomide, focus on directly killing cancer cells or inhibiting their DNA replication. However, ADI-PEG 20 targets the tumor's nutritional needs, potentially adding a new tool to the cancer-fighting arsenal. Additionally, the combination of ADI-PEG 20 with temozolomide and radiotherapy might enhance the overall effectiveness by attacking the cancer from multiple angles. This novel mechanism of action and the potential to improve treatment outcomes make this treatment an exciting prospect for researchers.

Research has shown that ADI-PEG 20 can help treat certain brain tumors, particularly when the tumor lacks a protein called ASS1, which some tumors need to grow. In this trial, participants in different cohorts will receive ADI-PEG 20 combined with Temozolomide (TMZ) and radiation therapy. Specifically, ADI-PEG 20, when combined with radiation therapy, has extended the time patients remain disease-free. Temozolomide (TMZ) improves survival rates when used with radiation, especially for severe brain tumors known as high-grade gliomas. Together, ADI-PEG 20 and TMZ offer a promising approach to fighting these aggressive brain cancers.⁴⁶⁷⁸⁹